Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of semaglutide injection versus originator semaglutide for weight management in adults with obesity without type 2 diabetes
CTR20243310Phase 3Completed
- Sponsor
- The United Laboratories International Holdings
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by The United Laboratories International Holdings. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20243310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243310.